Maciej T Wybraniec1, Katarzyna Mizia-Stec1. 1. First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.
Abstract
BACKGROUND: Contrast-induced acute kidney injury (CI-AKI) remains one of the crucial issues related to the development of invasive cardiology. The massive use of contrast media exposes patients to a great risk of contrast-induced nephropathy and chronic kidney disease development, and increases morbidity and mortality rates. The serum creatinine concentration does not allow for a timely and accurate CI-AKI diagnosis; hence numerous other biomarkers of renal injury have been proposed. Renalase, a novel catecholamine-metabolizing amine oxidase, is synthesized mainly in proximal tubular cells and secreted into urine and blood. It is primarily engaged in the degradation of circulating catecholamines. Notwithstanding its key role in blood pressure regulation, renalase remains a potential CI-AKI biomarker, which was shown to be markedly downregulated in the aftermath of renal injury. In this sense, renalase appears to be the first CI-AKI marker revealing an actual loss of renal function and indicating disease severity. SUMMARY: The purpose of this review is to summarize the contemporary knowledge about the application of novel biomarkers of CI-AKI and to highlight the potential role of renalase as a functional marker of contrast-induced renal injury. KEY MESSAGES: Renalase may constitute a missing biochemical link in the mutual interplay between kidney and cardiac pathology known as the cardiorenal syndrome.
BACKGROUND: Contrast-induced acute kidney injury (CI-AKI) remains one of the crucial issues related to the development of invasive cardiology. The massive use of contrast media exposes patients to a great risk of contrast-induced nephropathy and chronic kidney disease development, and increases morbidity and mortality rates. The serum creatinine concentration does not allow for a timely and accurate CI-AKI diagnosis; hence numerous other biomarkers of renal injury have been proposed. Renalase, a novel catecholamine-metabolizing amine oxidase, is synthesized mainly in proximal tubular cells and secreted into urine and blood. It is primarily engaged in the degradation of circulating catecholamines. Notwithstanding its key role in blood pressure regulation, renalase remains a potential CI-AKI biomarker, which was shown to be markedly downregulated in the aftermath of renal injury. In this sense, renalase appears to be the first CI-AKI marker revealing an actual loss of renal function and indicating disease severity. SUMMARY: The purpose of this review is to summarize the contemporary knowledge about the application of novel biomarkers of CI-AKI and to highlight the potential role of renalase as a functional marker of contrast-induced renal injury. KEY MESSAGES: Renalase may constitute a missing biochemical link in the mutual interplay between kidney and cardiac pathology known as the cardiorenal syndrome.
Authors: Isidro Torregrosa; Carmina Montoliu; Amparo Urios; María Jesús Andrés-Costa; Carla Giménez-Garzó; Isabel Juan; María Jesús Puchades; María Luisa Blasco; Arturo Carratalá; Rafael Sanjuán; Alfonso Miguel Journal: Heart Vessels Date: 2014-07-03 Impact factor: 2.037
Authors: Amar Narula; Roxana Mehran; Giora Weisz; George D Dangas; Jennifer Yu; Philippe Généreux; Eugenia Nikolsky; Sorin J Brener; Bernhard Witzenbichler; Giulio Guagliumi; Avery E Clark; Martin Fahy; Ke Xu; Bruce R Brodie; Gregg W Stone Journal: Eur Heart J Date: 2014-03-06 Impact factor: 29.983
Authors: Daria Sizova; Heino Velazquez; Benedita Sampaio-Maia; Janete Quelhas-Santos; Manuel Pestana; Gary V Desir Journal: Am J Physiol Renal Physiol Date: 2013-07-17
Authors: Huan Huang; Avery L McIntosh; Gregory G Martin; Kerstin K Landrock; Danilo Landrock; Shipra Gupta; Barbara P Atshaves; Ann B Kier; Friedhelm Schroeder Journal: FEBS J Date: 2014-04-07 Impact factor: 5.542